KRYSKrystal Biotech, Inc.
$331.81+103% 1Y
$331.81
$161.1552 weeks$371.35
KRYS in its own filings
Nothing in KRYS's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
168
Events found in the filings · across 508 filings · the record starts in 2017
- Hard flags
- none
Hard flags
- Most recent filing
- Aug 3, 2026
Most recent filing · Form 8-K
- Record starts
- Aug 11, 2017
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 2, 2026
- Change in certifying accountanthistorical
- 2022-05-26
- SEC comment-letter activity12 occurrences
- 2023-04-24
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 3, 2026Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results.Earnings release · press release
- Jul 21, 2026On July 21, 2026, Krystal Biotech, Inc. (the “Company”) filed with the U.S. Patent and Trademark Office a response to an Office Action in connection with a published patent application relating to KB801, the Company’s investigational gene therapy product candidate for the treatment of neurotrophic keratitis.Other event · Form 8-K
- May 4, 2026Krystal Biotech Announces First Quarter 2026 Financial and Operating Results.Material event (exhibits only) · press release
- Feb 17, 2026Krystal Biotech Announces Fourth Quarter and Full Year 2025.Earnings release · press release
- Dec 23, 2025On December 22, 2025, Kirti Ganorkar gave notice of his resignation from the Board of Directors (the “Board”) of Krystal Biotech, Inc. (the “Company”)Director or officer change · Form 8-K
- Nov 3, 2025Krystal Biotech Announces Third Quarter 2025.Earnings release · press release
- Oct 22, 2025Krystal Biotech, Inc. today reported that, effective as of October 22, 2025, its wholly owned subsidiary, Krystal Biotech Japan KK, commenced the commercial launch of VYJUVEK ® (beremagene geperpavec) in Japan for the treatment of dystrophic epidermolysis bullosa following its inclusion on Japan’s National Health …Other event · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks